Not at $13. Shareholders wouldn't allow it. Minimum would be $20... maybe. It's just too premature... if our myeloma product gets orphan drug status with the FDA our pps would instantly be north of that IMO and we have SEVERAL other "drugs" in development as well. Personally I think $40 - $50 minimum would be a good price. That would leave plenty of money on the table for the buyer to make money on the acquisition as well.